Compass Pathways PLC (CMPS) Dividendos

Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 156 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.